A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study
2021 ◽
Vol 26
(5)
◽
pp. 951-953
2020 ◽
Vol 115
(1)
◽
pp. S23-S24
Keyword(s):
Keyword(s):
2021 ◽
Vol 116
(1)
◽
pp. S1324-S1324
Keyword(s):